Cartesian Therapeutics (RNAC) jumped over 30% on Tuesday after announcing a licensing deal to develop its CAR-T cell ...
Cartesian Therapeutics, Inc. RNAC stock is up on Tuesday as the company is announcing a strategic licensing agreement with ...
WestGene’s established targeted LNP platform combined with Cartesian’s mRNA payload from Descartes-08 integrates two independently, clinically tested technologies for rapid clinical translation Plans ...
Shares of Cartesian Therapeutics rose in premarket trading Tuesday after the company struck a deal to use WestGene Biopharma's lipid-nanoparticle delivery technology for its therapies for autoimmune ...
Detailed price information for Cartesian Therapeutics Inc (RNAC-Q) from The Globe and Mail including charting and trades.
Detailed price information for Cartesian Therapeutics Inc (RNAC-Q) from The Globe and Mail including charting and trades.
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) on Tuesday revealed 12-month efficacy and safety data from the Phase 2b trial of Descartes-08, lead cell therapy candidate, in participants with generalized ...
WestGene's established targeted LNP platform combined with Cartesian's mRNA payload from Descartes-08 integrates two independently, clinically tested technologies for rapid clinical translation Plans ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results